Swedbank AB Sells 2,184 Shares of Avantor, Inc. (NYSE:AVTR)

Swedbank AB lowered its stake in Avantor, Inc. (NYSE:AVTR) by 2.0% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 104,998 shares of the company’s stock after selling 2,184 shares during the quarter. Swedbank AB’s holdings in Avantor were worth $2,716,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. Sound Shore Management Inc. CT purchased a new stake in Avantor in the 2nd quarter worth $76,412,000. Seven Eight Capital LP purchased a new stake in Avantor in the 2nd quarter worth $642,000. New York State Teachers Retirement System purchased a new stake in Avantor in the 3rd quarter worth $8,473,000. Allspring Global Investments Holdings LLC lifted its stake in Avantor by 35.1% in the 2nd quarter. Allspring Global Investments Holdings LLC now owns 1,157,855 shares of the company’s stock worth $24,547,000 after purchasing an additional 300,579 shares in the last quarter. Finally, WINTON GROUP Ltd purchased a new stake in Avantor in the 2nd quarter worth $952,000. Hedge funds and other institutional investors own 95.08% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently issued reports on AVTR. Robert W. Baird decreased their target price on shares of Avantor from $27.00 to $26.00 and set an “outperform” rating on the stock in a research report on Monday, October 28th. UBS Group decreased their target price on shares of Avantor from $30.00 to $29.00 and set a “buy” rating on the stock in a research report on Tuesday, October 8th. Wells Fargo & Company decreased their target price on shares of Avantor from $30.00 to $28.00 and set an “overweight” rating on the stock in a research report on Monday, October 28th. Barclays decreased their target price on shares of Avantor from $28.00 to $25.00 and set an “overweight” rating on the stock in a research report on Friday, October 25th. Finally, Royal Bank of Canada restated an “outperform” rating and set a $34.00 target price on shares of Avantor in a research report on Thursday, September 26th. Three research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $27.57.

Insider Transactions at Avantor

In other news, CAO Steven W. Eck sold 3,525 shares of the firm’s stock in a transaction that occurred on Thursday, September 5th. The shares were sold at an average price of $25.06, for a total transaction of $88,336.50. Following the transaction, the chief accounting officer now directly owns 29,544 shares of the company’s stock, valued at approximately $740,372.64. This trade represents a 10.66 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 1.30% of the company’s stock.

Avantor Price Performance

Shares of AVTR stock opened at $21.04 on Thursday. The company has a market capitalization of $14.32 billion, a P/E ratio of 45.74, a P/E/G ratio of 2.56 and a beta of 1.35. The company’s 50-day simple moving average is $23.53 and its two-hundred day simple moving average is $23.78. Avantor, Inc. has a one year low of $19.59 and a one year high of $28.00. The company has a debt-to-equity ratio of 0.84, a current ratio of 1.54 and a quick ratio of 1.06.

About Avantor

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.